Pipelines and Patients Drive Finished Dosage Opportunities

April 22, 2019

Efforts to ease patient burden with multi-API products and the increasing number of candidate products with low bioavailability are creating opportunities for contract manufacturing and development organizations (CDMOs) to create value with innovative, but complex, finished dosage formulations. Providing patients with solutions that allow them to dose less frequently and reduce complexity are a major selling point, CDMOs say. The emergence of smaller-volume products is creating practical challenges, however, for process design and scale-up.

Spotlight

Mangalam Drugs & Organics Ltd

Mangalam Drugs & Organics Limitedcommenced its manufacturing of Active Pharmaceutical Ingredients (APIs) and Intermediates at VAPI – Gujarat in 1977. It has a multi product manufacturing facility on two locations, and an in-house R&D laboratory. Over the last three decades Mangalam has acquired worldwide reputation as a single stop destination for frontline Anti malarials.

OTHER WHITEPAPERS
news image

Global Use of Medicines 2023

whitePaper | January 18, 2023

Reaching a post-pandemic era is an alluring prospect for almost everyone around the world after the disruptions of the past three years.

Read More
news image

Winning with biosimilars Opportunities in global markets

whitePaper | March 14, 2022

Over the past several years, biologics have gained significant traction in the pharmaceutical industry, representing more than $150 billion in global sales in 2013. By 2020 they are predicted to generate $290 billion in revenue and comprise 27 percent of the pharmaceutical market.i

Read More
news image

Discovering Effective Strategies for Sales and Marketing in the Face of Reduced Access to Oncologists

whitePaper | January 15, 2023

Oncology breakthroughs are currently fueling significant growth in the market, as well as the competition between pharmaceutical brands for market share. As increasingly individualized cancer treatments become available,

Read More
news image

QbD and PAT in Biopharmaceutical Development

whitePaper | July 12, 2022

As the pharmaceutical industry tries to embrace the methodologies of quality by design (QbD) provided by the FDA ’s process validation (PV) guidance (1) and International Conference on Harmonization.

Read More
news image

Latest Evidence and Effects of Vitamin D3 (cholecalciferol)-Drug Interactions

whitePaper | October 15, 2022

Because vitamin D receptors are present in most cells in the body, its active form has potent effects on the growth and differentiation of many types of cells, meaning that vitamin D

Read More
news image

Shining a Light on Lipid Nanoparticle Characterization

whitePaper | October 3, 2022

Next-Generation Synthetic Biology Workflow Platform Codex DNA’s BioXp 9600 system is a next-generation high throughput platform intended for automated synthesis of gene fragments and clones from digital sequences.

Read More

Spotlight

Mangalam Drugs & Organics Ltd

Mangalam Drugs & Organics Limitedcommenced its manufacturing of Active Pharmaceutical Ingredients (APIs) and Intermediates at VAPI – Gujarat in 1977. It has a multi product manufacturing facility on two locations, and an in-house R&D laboratory. Over the last three decades Mangalam has acquired worldwide reputation as a single stop destination for frontline Anti malarials.

Events